Litcius/Paper detail

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde

2020Annals of the Rheumatic Diseases2,767 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAntirheumatic drugsRheumatoid arthritisAntirheumatic AgentsDisease managementIntensive care medicineArthritisDiseaseBiological drugsPhysical therapyInternal medicineParkinson's diseaseRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical MethodsSystemic Lupus Erythematosus Research